Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.
An exciting industry consisting of companies who develop new drugs to combat such diseases as cancer and other life-threatening diseases. Some may also participate in gene therapy. These firms either bring new drugs to the market themselves (which is a grueling process) or they sell their technology to bigger pharmaceutical companies.
|
| Totals |
Company |
Industry |
| Sales: |
$223.8 Mil |
$96,330.8 Mil |
| Market Cap: |
$3,404.7 Mil |
$466,832.4 Mil |
| Analysts Recommendation: |
Buy |
Buy |
|
|
| Averages |
Company |
Industry |
 |
| Growth |
| Historic Revenue: |
79.2% |
96.4% |
| Estimated Revenue: |
N/A |
17.6% |
| Historic Earnings: |
N/A |
(8.3%) |
| Estimated Earnings: |
N/A |
14.8% |
| Stock Price (1 Year): |
10.4% |
88.4% |
| Cash per Share: |
92.8% |
22.9% |
| Dividend: |
N/A |
N/A |
| Price |
| Trailing PE: |
N/A |
N/A |
| Forward PE: |
N/A |
106.1 |
| Price-to-Sales: |
15.2 |
N/A |
| Price-to-Book: |
7.1 |
5.9 |
| Dividend Yield: |
N/A |
N/A |
| Market Cap: |
$3,404.7 Mil |
$10,148.5 Mil |
| Operations |
| Net Margin: |
(109.6%) |
(408.9%) |
| Gross Margin: |
94.5% |
71.6% |
| Return on Equity: |
(.5) |
(.6) |
| Return on Assets: |
(.5) |
(.2) |
| Balance Sheet |
| Current Ratio: |
8.8 |
5.5 |
| Quick Ratio: |
8.8 |
5.1 |
| Cash Ratio: |
7.9 |
4.0 |
| Debt-to-Equity: |
.1 |
1.3 |
| Interest Coverage: |
N/A |
1.3 |
| Technicals |
| Relative-Strength Index: |
63.7 |
46.1 |
|
|
|
